Skip to content
Medical Health Aged Care, Research Development

Stroke associated with long-term cognitive decline

Centre for Healthy Brain Ageing, UNSW Sydney 3 mins read

UNDER EMBARGO: 2 October 11am US Eastern time | 3 October 1am Sydney AEST time 

New evidence from the Centre for Healthy Brain Ageing (CHeBA) indicates that older adults who experience a stroke for the first time will have substantial immediate and accelerated long term-cognitive decline. 

Stroke is a leading cause of disability and dementia globally, with projections indicating a continued rise in both prevalence and burden. The new research, published today in JAMA Network Open, looked at finding out exactly how a stroke impacts a person’s cognitive abilities.

Stroke occurs when blood flow to part of the brain is blocked or reduced, causing damage to brain cells. Previous research from the Centre has shown that more than a third of stroke survivors’ ability to think, remember and make decisions is significantly disadvantaged after stroke, with clear deficits in cognition or vascular dementia present.

Vascular dementia, the second most common type of dementia, is caused by reduced blood flow to the brain. The research, led by biostatistician and Research Associate Jess Lo, addressed many unanswered questions about this dementia type, which is yet to be studied as extensively as Alzheimer’s disease.

“Although we do experience changes to our brain functioning over time and as we age, certain medical conditions can potentially speed up these changes, which may lead to cognitive impairment or dementia,” says Lo.

“We wanted to understand exactly how stroke affects cognitive abilities such as thinking, memory and decision-making, and what the impacts are both short and long term,” she said.

The research analysed data from 14 studies that followed community dwelling older adults without a history of stroke or dementia, with an average age of 73 over many years, tracking their health and cognitive abilities. The studies, part of the CHeBA-led international Cohort Studies of Memory in an International Consortium (COSMIC), span 11 countries including Australia, Brazil, France and the US.

With data from 20,860 participants, the researchers identified people who experienced their first stroke during the study period.

“By analysing their cognitive abilities over several assessment time points before and after stroke, we mapped out the course of changes in their thinking and memory over the periods before and after stroke, and therefore, were able to determine the changes in cognitive ability due to a stroke,” said Lo.

The research observed a moderate rate of cognitive decline in all individuals before any stroke, which may be related to ageing and health conditions typical of someone around 73 years old. However, the research also revealed that for older adults experiencing a stroke there was an associated significant immediate drop in cognitive ability in all areas of cognitive performance, followed by a gradual long-term decline.

“After a stroke, the rate of decline accelerated slightly compared to the rate before the stroke. Areas of cognitive performance affected included language, processing speed, and executive function,” said Lo.

The research also found that individuals who had a history of diabetes, hypertension, high cholesterol, cardiovascular disease, depression, smoked or were APOE4 carriers exhibited significantly faster cognitive decline before any stroke.

“This supports the hypothesis that vascular risk factors exert their greatest impact on cognitive function years before stroke onset,” said Lo. “Targeting modifiable risk factors at an early stage may reduce the risk of stroke but also subsequent risk of stroke-related cognitive decline and cognitive impairment.”

Senior author on the paper and Co-Director of the Centre for Healthy Brain Ageing (CHeBA), Professor Perminder Sachdev, said that this global collaborative study highlights the significant and lasting negative impact of stroke on brain cognition.

“Our findings can help clinicians better plan for the ongoing needs of stroke survivors who are at risk of disability and a lower quality of life,” said Professor Sachdev.

 

Funding: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG057531.

 

  • ENDS -

About us:

CHeBA is a self-funded research centre with a vision to achieve, through research, healthier brain ageing and better clinical care of age-related brain diseases. Centre for Healthy Brain Ageing (CHeBA) (unsw.edu.au)


Contact details:

Helena Hudson

h.hudson@unsw.edu.au

+61 414292383

Media

More from this category

  • Medical Health Aged Care
  • 16/01/2025
  • 08:41
Mainstay Medical Holdings plc

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and…

  • Contains:
  • Medical Health Aged Care
  • 16/01/2025
  • 06:05
Royal Australian College of GPs

ADHD reform more urgent in NSW with psychiatrists’ workforce crisis

The Royal Australian College of GPs is urging the New South Wales Government to prioritise reforms to improve access to support and treatment for people with attention deficit hyperactivity disorder (ADHD) from GPs after the mass resignation of psychiatrists. Around 200 psychiatrists in NSW's public health system have submitted their resignations amid an ongoing pay dispute with the state government. RACGP New South Wales Chair Dr Rebekah Hoffman said: “GPs should be able to initiate and prescribe medications for people living with ADHD, and manage their care. Allowing GPs to give more support to people living with ADHD will improve…

  • Medical Health Aged Care
  • 16/01/2025
  • 05:00
GlaxoSmithKline

Local scientific discovery Omjarra (momelotinib) now TGA approved for Australians with rare bone marrow cancer

Embargoed: 06.00am Thursday 16th January 2025, MELBOURNE, AUSTRALIA Omjjara (momelotinib) was discovered by Melbourne scientists in 2005.1 Today’s TGA approval follows its recent FDA approval and makes it one of only a handful of original Australian scientific discoveries to secure both milestones.1-6 Omjjara is a once daily pill indicated to treat disease-related consequences of primary or secondary myelofibrosis including spleen enlargement and moderate to severe anaemia.7 Myelofibrosis is a rare bone marrow cancer with an average survival of 5-7 years.7-8 GSK Australia welcomes the Therapeutic Goods Administration (TGA) approval of Omjjara - a local scientific discovery now providing the first…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.